Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas

被引:67
作者
Pavel, ME
Hassler, G
Baum, U
Hahn, EG
Lohmann, T
Schuppan, D
机构
[1] Univ Hosp Erlangen Nuernberg, Dept Med 1, D-91054 Erlangen, Germany
[2] Univ Hosp Erlangen Nuernberg, Inst Diagnost Radiol, D-91054 Erlangen, Germany
关键词
D O I
10.1111/j.1365-2265.2005.02238.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective The growth behaviour of well-differentiated neuroendocrine carcinomas of the gastro-entero-pancreatic system varies greatly and parameters predicting their prognosis are lacking. The aim of our study was to investigate whether tumour growth could be correlated with the release of proangiogenic factors into the circulation. Patients and methods Circulating vascular endothelial growth factor (VEGF), interleukin-8 (IL-8), basic fibroblast growth factor (bFGF) and angiogenin were measured in 38 patients with advanced neuroendocrine carcinomas and compared to healthy age-matched controls. In 20 patients, angiogenic cytokine levels were measured at consecutive time points and correlated to tumour progression as assessed by abdominal CT scan, MRI and chromogranin A levels. Results VEGF levels were elevated in patients compared to controls (P < 0.002) and clearly associated with tumour progression (P < 0.005). Angiogenin levels were significantly higher in patients than in controls (P < 0.003), while high IL-8 levels were predictive of shorter survival. Angiogenin and bFGF levels were correlated neither with tumour growth nor with patient survival. Conclusions VEGF and IL-8 are associated with tumour progression and might qualify as markers of prognosis and therapy control in patients with neuroendocrine carcinomas. Our results support the notion that specific anti-angiogenic therapies should be evaluated in neuroendocrine carcinoma patients.
引用
收藏
页码:434 / 443
页数:10
相关论文
共 56 条
[1]  
Barton DPJ, 1997, CLIN CANCER RES, V3, P1579
[2]  
Belgore FM, 2001, AM J HEMATOL, V66, P59, DOI 10.1002/1096-8652(200101)66:1<59::AID-AJH1011>3.0.CO
[3]  
2-Z
[4]  
BENDER H, 1992, CLIN CHEM, V38, P2267
[5]   Inhibition of vascular endothelial growth factor by octreotide in colorectal cancer patients [J].
Cascinu, S ;
Del Ferro, E ;
Ligi, M ;
Staccioli, MP ;
Giordani, P ;
Catalano, V ;
Agostinelli, R ;
Muretto, P ;
Catalano, G .
CANCER INVESTIGATION, 2001, 19 (01) :8-12
[6]  
Chen JJW, 2003, CLIN CANCER RES, V9, P729
[7]   Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients [J].
Dirix, LY ;
Vermeulen, PB ;
Pawinski, A ;
Prove, A ;
Benoy, I ;
DePooter, C ;
Martin, M ;
VanOosterom, AT .
BRITISH JOURNAL OF CANCER, 1997, 76 (02) :238-243
[8]   Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients [J].
Eppenberger, U ;
Kueng, W ;
Schlaeppi, JM ;
Roesel, JL ;
Benz, C ;
Mueller, H ;
Matter, A ;
Zuber, M ;
Luescher, K ;
Litschgi, M ;
Schmitt, M ;
Foekens, JA ;
Eppenberger-Castori, S .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (09) :3129-3136
[9]  
Etoh T, 2000, CLIN CANCER RES, V6, P3545
[10]   Chromogranin A measurement in neuroendocrine tumors [J].
Ferrari, L ;
Seregni, E ;
Martinetti, A ;
Van Graafeiland, B ;
Nerini-Molteni, S ;
Botti, C ;
Artale, S ;
Cresta, S ;
Bombardieri, E .
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 1998, 13 (01) :3-9